Investors sentiment decreased to 0.78 in 2018 Q4. Its down 0.10, from 0.88 in 2018Q3. It dropped, as 89 investors sold BMY shares while 550 reduced holdings. 126 funds opened positions while 371 raised stakes. 1.16 billion shares or 2.02% more from 1.14 billion shares in 2018Q3 were reported. Goldman Sachs Gru Incorporated Inc reported 12.07 million shares stake. Aviance Cap Mgmt Ltd Liability Corporation reported 70,453 shares. Brinker Capital reported 45,268 shares or 0.1% of all its holdings. Terril Brothers Incorporated accumulated 492,489 shares. Hudson Bay Capital Ltd Partnership holds 0.03% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 47,400 shares. Moreover, Atwood And Palmer has 0.1% invested in Bristol-Myers Squibb Company (NYSE:BMY). Marshwinds Advisory invested 1.2% in Bristol-Myers Squibb Company (NYSE:BMY). Kessler Investment Gru Incorporated reported 0.1% stake. Forbes J M & Company Llp holds 11,525 shares. Bnp Paribas Asset Mngmt Hldg Sa holds 1.22 million shares or 0.57% of its portfolio. Moreover, Cutter And Brokerage has 0.69% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 35,081 shares. M Hldgs reported 14,327 shares. Sectoral Asset invested in 257,197 shares. Rodgers Brothers Inc holds 0% or 4,431 shares in its portfolio. Roundview Limited Liability Com holds 0.45% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 30,588 shares.
D-E Shaw & Company Inc increased its stake in Bristol Myers Squibb Co (BMY) by 3002.65% based on its latest 2018Q4 regulatory filing with the SEC. D-E Shaw & Company Inc bought 11.50 million shares as the company’s stock rose 2.02% with the market. The hedge fund held 11.88 million shares of the major pharmaceuticals company at the end of 2018Q4, valued at $617.69M, up from 383,000 at the end of the previous reported quarter. D-E Shaw & Company Inc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be bullish on the $81.57 billion market cap company. The stock increased 0.14% or $0.07 during the last trading session, reaching $49.96. About 27.37 million shares traded or 46.14% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 19.24% since March 17, 2018 and is downtrending. It has underperformed by 23.61% the S&P500.
D-E Shaw & Company Inc, which manages about $81.36B and $72.58 billion US Long portfolio, decreased its stake in Haemonetics Corp (NYSE:HAE) by 87,525 shares to 239,571 shares, valued at $23.97M in 2018Q4, according to the filing. It also reduced its holding in Svb Finl Group (Put) (NASDAQ:SIVB) by 22,700 shares in the quarter, leaving it with 11,700 shares, and cut its stake in United Parcel Service Inc (Call) (NYSE:UPS).
More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers Squibb’s Opdivo flunks late-stage lung cancer study – Seeking Alpha” on October 12, 2018, also Seekingalpha.com with their article: “Celgene: Long The Deal Spread – Seeking Alpha” published on January 29, 2019, Seekingalpha.com published: “Bristol-Myers positive RCC data pressures Nektar, down 10% – Seeking Alpha” on February 12, 2019. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “A Special Situation Set Up By Bristol-Myers Squibb’s Offer For Celgene – Seeking Alpha” published on February 11, 2019 as well as Seekingalpha.com‘s news article titled: “Starboard said to take stake in Bristol-Myers Squibb – Seeking Alpha” with publication date: February 02, 2019.
Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage
Among 9 analysts covering Bristol-Myers Squibb (NYSE:BMY), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Bristol-Myers Squibb had 14 analyst reports since October 8, 2018 according to SRatingsIntel. The rating was maintained by JP Morgan with “Overweight” on Monday, October 8. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, November 16 with “Market Perform” rating. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Hold” rating given on Tuesday, November 27 by Guggenheim. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday, October 23 with “Market Perform” rating. The firm has “Outperform” rating given on Thursday, December 6 by BMO Capital Markets. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Neutral” rating by Bank of America on Tuesday, February 19. The rating was maintained by Morgan Stanley with “Equal-Weight” on Tuesday, November 6. Citigroup downgraded the stock to “Neutral” rating in Monday, October 22 report. Barclays Capital maintained it with “Equal-Weight” rating and $58 target in Friday, October 12 report. As per Thursday, February 28, the company rating was maintained by BMO Capital Markets.